期刊
MOLECULAR THERAPY-NUCLEIC ACIDS
卷 16, 期 -, 页码 543-553出版社
CELL PRESS
DOI: 10.1016/j.omtn.2019.04.004
关键词
-
资金
- National Natural Science Foundation of China [81372321, 81472200, 81572261, 81702377, 81702256]
- Innovation Capability Development Project of Jiangsu Province [BM2015004]
- Project of Jiangsu Provincial Medical Talent [ZDRCA2016033]
- Natural Science Foundation of Beijing [7182169]
- Key Project of Cutting-edge Clinical Technology of Jiangsu Province [BE2016797]
- Postdoctoral Fellowship of the Peking-Tsinghua Center for Life Sciences
Emerging evidence demonstrates that long non-coding RNAs (lncRNAs) are deeply involved in the development of various cancers. This study identified that SBF2-AS1, an early-stagespecific lncRNA, is critical for the tumorigenesis of lung adenocarcinoma (LUAD). We first analyzed LUAD transcriptome data from The Cancer Genome Atlas and the GEO database by weighted gene co-expression network analysis (WGCNA). Five early LUAD-specific lncRNAs were filtered out, and only SBF2-AS1 was upregulated in LUAD. High expression of SBF2-AS1 indicates poor survival of LUAD, especially the early-stage LUAD, but not lung squamous cell carcinoma. SBF2-AS1 promotes LUAD cells proliferation in vitro, and RNA-sequencing data shows that many cell-cycle-related genes were downregulated after SBF2-AS1 knockdown. Mechanically, SBF2-AS1 could competitively bind with miR-338-3p and miR-362-3p to increase E2F1 expression. Finally, we show that the SBF2-AS1-miR-338-3p/362-3p-E2F1 axis could promote LUAD tumorigenesis in vitro and in vivo. Our study demonstrates that SBF2-AS1, an early-stage-specific lncRNA, promotes LUAD tumorigenesis by sponging miR-338-3p and miR-362-3p and increasing E2F1 expression. The SBF2-AS1-miR-338-3p/362-3p-E2F1 regulatory axis may serve as a prognostic marker and potential therapeutic target for LUAD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据